Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
NCT04089527
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG:
CC-95775
Sponsor
Celgene